share_log

4: Statement of changes in beneficial ownership of securities-Officer Wolfe Peter

4: Statement of changes in beneficial ownership of securities-Officer Wolfe Peter

4:持股變動聲明-高管 Wolfe Peter
美股SEC公告 ·  07/19 09:36

Moomoo AI 已提取核心訊息

Peter Wolfe, the Chief Financial Officer of ZyVersa Therapeutics, Inc. (ZVSA), was involved in a transaction with the company's stock on May 24, 2023. The specific details of the transaction, such as the number of shares traded, the nature of the shares, the transaction price, and the total value of the transaction, were not disclosed in the announcement. Consequently, Wolfe's number of shares held after the transaction remains unknown. This information is critical for investors to understand the potential impact of the transaction on their investment decisions.
Peter Wolfe, the Chief Financial Officer of ZyVersa Therapeutics, Inc. (ZVSA), was involved in a transaction with the company's stock on May 24, 2023. The specific details of the transaction, such as the number of shares traded, the nature of the shares, the transaction price, and the total value of the transaction, were not disclosed in the announcement. Consequently, Wolfe's number of shares held after the transaction remains unknown. This information is critical for investors to understand the potential impact of the transaction on their investment decisions.
致富金融(臨時代碼)的首席財務官彼得·沃爾夫於2023年5月24日與公司的股票進行了交易。該交易的具體細節,例如交易的股票數量、股票性質、交易價格以及交易總價值,並未在公告中披露。因此,沃爾夫在交易後持有的股票數量仍然未知。投資者了解交易對他們的投資決策的潛在影響至關重要。
致富金融(臨時代碼)的首席財務官彼得·沃爾夫於2023年5月24日與公司的股票進行了交易。該交易的具體細節,例如交易的股票數量、股票性質、交易價格以及交易總價值,並未在公告中披露。因此,沃爾夫在交易後持有的股票數量仍然未知。投資者了解交易對他們的投資決策的潛在影響至關重要。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息